Breast Carcinoma
|
|
0.770 |
GeneticVariation
|
BEFREE |
BC patients (n = 1687) randomly sampled in an adjuvant, randomized phase III trial (SUCCESS A study) were genotyped for nine BC risk SNPs: rs17468277 <i>(CASP8)</i> , rs2981582 <i>(FGFR2)</i> , rs13281615(8q24), rs3817198 <i>(LSP1)</i> , rs889312 <i>(MAP3K1)</i> , rs3803662 <i>(TOX3)</i> , rs13387042(2q35), rs4973768 <i>(SLC4A7)</i> , rs6504950 <i>(COX11)</i> .
|
28757652 |
2017 |
Breast Carcinoma
|
|
0.770 |
GeneticVariation
|
BEFREE |
We identified 28 highly correlated common variants, in a 53 Kb region spanning two introns of the STXBP4 gene, that are strong candidates for driving breast cancer risk (lead SNP rs2787486 (OR = 0.92; CI 0.90-0.94; P = 8.96 × 10(-15))) and are correlated with two previously reported risk-associated variants at this locus, SNPs rs6504950 (OR = 0.94, P = 2.04 × 10(-09), r(2) = 0.73 with lead SNP) and rs1156287 (OR = 0.93, P = 3.41 × 10(-11), r(2) = 0.83 with lead SNP).
|
27600471 |
2016 |
Breast Carcinoma
|
|
0.770 |
GeneticVariation
|
GWASCAT |
Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer.
|
25751625 |
2015 |
Breast Carcinoma
|
|
0.770 |
GeneticVariation
|
BEFREE |
We confirmed associations between rs13387042 (2q35), rs4973768 (SLC4A7), rs10941679 (5p12), rs2981582 (FGFR2), rs3817198 (LSP1), rs3803662 (TOX3), and rs6504950 (STXBP4) with breast cancer.
|
23893088 |
2013 |
Breast Carcinoma
|
|
0.770 |
GeneticVariation
|
GWASCAT |
Large-scale genotyping identifies 41 new loci associated with breast cancer risk.
|
23535729 |
2013 |
Breast Carcinoma
|
|
0.770 |
GeneticVariation
|
BEFREE |
The study results suggest that previously identified breast cancer risk susceptibility loci, rs12443621 (16q12) and rs6504950 (17q23), may influence breast cancer prognosis or comorbid conditions associated with overall survival.
|
23635555 |
2013 |
Breast Carcinoma
|
|
0.770 |
GeneticVariation
|
BEFREE |
We observed that STXBP4/COX11 rs6504950 polymorphism was significantly correlated with breast cancer risk when all studies were pooled into the meta-analysis (the allele contrast model: OR = 0.93, 95% CI = 0.87-0.99; the heterozygote codominant model: OR = 0.87, 95% CI = 0.83-0.90; the dominant model OR = 0.92, 95% CI = 0.88-0.96).
|
22863968 |
2012 |
Breast Carcinoma
|
|
0.770 |
GeneticVariation
|
BEFREE |
Confirmed BC risk SNPs rs17468277 (CASP8), rs1982073 (TGFB1), rs2981582 (FGFR2), rs13281615 (8q24), rs3817198 (LSP1), rs889312 (MAP3K1), rs3803662 (TOX3), rs13387042 (2q35), rs4973768 (SLC4A7), rs6504950 (COX11) and rs10941679 (5p12) were genotyped for 25 853 BC patients with the available follow-up; 62 other SNPs, which have been suggested as BC risk SNPs by a GWAS or as candidate SNPs from individual studies, were genotyped for replication purposes in subsets of these patients.
|
22532573 |
2012 |
Breast Carcinoma
|
|
0.770 |
GeneticVariation
|
BEFREE |
Neither SNP was associated with breast cancer risk for BRCA1 carriers, and rs6504950 was not associated with breast cancer for either BRCA1 or BRCA2 carriers.
|
21118973 |
2010 |
Breast Carcinoma
|
|
0.770 |
GeneticVariation
|
GWASCAT |
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2.
|
19330027 |
2009 |